Masashi Sakaki

Masashi Sakaki

Auto-generated profile, based on publicly available information

Masashi Sakaki

Division of Gastroenterology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2013 in Cancer Research
Verified
Journal Article
Closed access
PDF file
Gary KohanbashGary Kohanbash
Gary Kohanbash
KMKayla McKaveney
Kayla McKaveney
MSMasashi Sakaki
Masashi Sakaki
RURyo Ueda
Ryo Ueda
AMArlan H. Mintz
Arlan H. Mintz
HOHideho Okada
Hideho Okada
Malignant gliomas are lethal cancers in the brain and heavily infiltrated by myeloid cells. Interleukin-4 receptor-α (IL-4Rα) mediates the immunosuppressive functions of myeloid cells, and polymorphisms in the IL-4Rα gene are associated with altered glioma risk and prognosis. In this study, we sought to evaluate a hypothesized causal role for IL-4Rα and myeloid suppressor cells in glioma development. In both mouse de novo gliomas and human glioblastoma cases, IL-4Rα was upregulated on glioma-infiltrating myeloid cells but not in the periphery or in normal brain. Mice genetically deficient for IL-4Rα exhibited a slower growth of glioma associated with reduced production in the glioma microenvironment of arginase, a marker of myeloid suppressor cells, which is critical for their T-cell inhibitory function. Supporting this result, investigations using bone marrow-derived myeloid cells showed that IL-4Rα mediates IL-13–induced production of arginase. Furthermore, glioma-derived myeloid cells suppressed T-cell proliferation in an IL-4Rα–dependent manner, consistent with their identification as myeloid-derived suppressor cells (MDSC). Granulocyte macrophage colony-stimulating factor (GM-CSF) plays a central role for the induction of IL-4Rα expression on myeloid cells, and we found that GM-CSF is upregulated in both human and mouse glioma microenvironments compared with normal brain or peripheral blood samples. Together, our findings establish a GM-CSF–induced mechanism of immunosuppression in the glioma microenvironment via upregulation of IL-4Rα on MDSCs. Cancer Res; 73(21); 6413–23. ©2013 AACR.

28 June 2011 in Journal of Leukocyte Biology
Verified
Journal Article
Open access
PDF file
KTKazuyoshi Takeda
Kazuyoshi Takeda
MNMasafumi Nakayama
Masafumi Nakayama
MSMasashi Sakaki
Masashi Sakaki
YHYoshihiro Hayakawa
Yoshihiro Hayakawa
MIMichio Imawari
Michio Imawari
MSMark J. Smyth
Mark J. Smyth
NK cells are effector lymphocytes playing a critical role in the natural resistance against tumors. However, the precise mechanisms underlying NK cell-mediated natural resistance against tumor metastasis are still unrevealed. B16 cells, mouse melanoma cells, were resistant to freshly isolated NK cell-mediated killing; nevertheless, NK cells were critical for natural resistance against experimental lung metastasis of B16 cells. We found that lung metastasis was increased significantly in IFN-γ–/– mice but not pfp–/–, IFN-αR–/–, or IL-12/IL-18–/– mice. Interestingly, freshly isolated lung NK cells, but not spleen or liver NK cells, displayed augmented IFN-γ production after B16 inoculation. Adoptive transfer of pfp–/– NK cells, but not IFN-γ–/– NK cells, significantly decreased B16 lung metastasis in IFN-γ–/– and pfp/IFN-γ–/–mice. Lung metastases of IFN-γRDN B16 was also increased in NK cell-depleted or IFN-γ–/– mice, suggesting that the IFN-γ response of host cells was required in the NK cell and IFN-γ-mediated antimetastatic effect. Our results demonstrate that IFN-γ production from lung resident NK cells is a key response in the natural resistance to the experimental lung metastasis of NK cell-resistant tumor cells.

20 November 2009 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
KHKazumasa Hiroishi
Kazumasa Hiroishi
JEJunichi Eguchi
Junichi Eguchi
TBToshiyuki Baba
Toshiyuki Baba
TSTomoe Shimazaki
Tomoe Shimazaki
SIShigeaki Ishii
Shigeaki Ishii
MIMichio Imawari
Michio Imawari

14 January 2015 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
HOHideho Okada
Hideho Okada
LBLisa H. Butterfield
Lisa H. Butterfield
RHRonald L. Hamilton
Ronald L. Hamilton
AHAki Hoji
Aki Hoji
MSMasashi Sakaki
Masashi Sakaki
FLFrank S. Lieberman
Frank S. Lieberman
Purpose: WHO grade 2 low-grade gliomas (LGG) with high risk factors for recurrence are mostly lethal despite current treatments. We conducted a phase I study to evaluate the safety and immunogenicity of subcutaneous vaccinations with synthetic peptides for glioma-associated antigen (GAA) epitopes in HLA-A2+ adults with high-risk LGGs in the following three cohorts: (i) patients without prior progression, chemotherapy, or radiotherapy (RT); (ii) patients without prior progression or chemotherapy but with prior RT; and (iii) recurrent patients. Experimental Design: GAAs were IL13Rα2, EphA2, WT1, and Survivin. Synthetic peptides were emulsified in Montanide-ISA-51 and given every 3 weeks for eight courses with intramuscular injections of poly-ICLC, followed by q12 week booster vaccines. Results: Cohorts 1, 2, and 3 enrolled 12, 1, and 10 patients, respectively. No regimen-limiting toxicity was encountered except for one case with grade 3 fever, fatigue, and mood disturbance (cohort 1). ELISPOT assays demonstrated robust IFNγ responses against at least three of the four GAA epitopes in 10 and 4 cases of cohorts 1 and 3, respectively. Cohort 1 patients demonstrated significantly higher IFNγ responses than cohort 3 patients. Median progression-free survival (PFS) periods since the first vaccine are 17 months in cohort 1 (range, 10–47+) and 12 months in cohort 3 (range, 3–41+). The only patient with large astrocytoma in cohort 2 has been progression-free for more than 67 months since diagnosis. Conclusion: The current regimen is well tolerated and induces robust GAA-specific responses in WHO grade 2 glioma patients. These results warrant further evaluations of this approach. Clin Cancer Res; 21(2); 286–94. ©2014 AACR.

16 November 2007 in Hepatology Research
Verified
Journal Article
Closed access
PDF file
MSMasashi Sakaki
Masashi Sakaki
KHKazumasa Hiroishi
Kazumasa Hiroishi
TBToshiyuki Baba
Toshiyuki Baba
TITakayoshi Ito
Takayoshi Ito
YHYuichi Hirayama
Yuichi Hirayama
MIMichio Imawari
Michio Imawari

8 May 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JZJia Zhong
Jia Zhong
MSMasashi Sakaki
Masashi Sakaki
HOHideho Okada
Hideho Okada
EAEric T Ahrens
Eric T Ahrens
Noninvasive biomarkers of anti-tumoral efficacy are of great importance to the development of therapeutic agents. Tumor oxygenation has been shown to be an important indicator of therapeutic response. We report the use of intracellular labeling of tumor cells with perfluorocarbon (PFC) molecules, combined with quantitative 19F spin-lattice relaxation rate (R1) measurements, to assay tumor cell oxygen dynamics in situ. In a murine central nervous system (CNS) GL261 glioma model, we visualized the impact of Pmel-1 cytotoxic T cell immunotherapy, delivered intravenously, on intracellular tumor oxygen levels. GL261 glioma cells were labeled ex vivo with PFC and inoculated into the mouse striatum. The R1 of 19F labeled cells was measured using localized single-voxel magnetic resonance spectroscopy, and the absolute intracellular partial pressure of oxygen (pO2) was ascertained. Three days after tumor implantation, mice were treated with 2×107 cytotoxic T cells intravenously. At day five, a transient spike in pO2 was observed indicating an influx of T cells into the CNS and putative tumor cell apoptosis. Immunohistochemistry and quantitative flow cytometry analysis confirmed that the pO2 was causally related to the T cells infiltration. Surprisingly, the pO2 spike was detected even though few (∼4×104) T cells actually ingress into the CNS and with minimal tumor shrinkage. These results indicate the high sensitivity of this approach and its utility as a non-invasive surrogate biomarker of anti-cancer immunotherapeutic response in preclinical models.